This Study Aims to Compare Asthma Control in Children Monitored With FeNO Against a Historical Cohort Without FeNO. Secondary Objectives Include Evaluating Associations Between FeNO Levels, ACT/C-ACT Scores, Eosinophil Counts, FEV1%, ICS Adherence, and Exacerbation Frequency.

FeNO Fractional Exhaled Nitric Oxide Test as Significant Tool in Enhancing Asthma Treatment Management Among Children

This study aims to evaluate whether incorporating FeNO monitoring into routine pediatric asthma care improves clinical outcomes relative to a historical cohort managed without FeNO

Inclusion Criteria:

• Children aged 6 to 14 years with a physician-diagnosed asthma.

  • Minimum of three months' follow-up at the pediatric respiratory clinic.
  • Availability of Asthma Control Test (ACT/C-ACT) scores and clinical data

Exclusion Criteria:

• Presence of other chronic pulmonary diseases (e.g., cystic fibrosis).

  • Recent respiratory infections within four weeks prior to enrollment.
  • Current treatment with biologic agents affecting asthma inflammation.